Treatment of Resistant Alopecia areata with Tofacitinib

The activity of tofacitinib for Alopecia areata (AA) has been reported but mainly from the western countries. We report the case of a young female Indian patient with AA unresponsive to therapy. Improvements in terms of hair regrowth were observed within 2 months of treatment with oral tofacitinib 5...

Descripción completa

Detalles Bibliográficos
Autor principal: Avhad, Ganesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069910/
https://www.ncbi.nlm.nih.gov/pubmed/35531489
http://dx.doi.org/10.4103/ijt.ijt_128_21
_version_ 1784700530019270656
author Avhad, Ganesh
author_facet Avhad, Ganesh
author_sort Avhad, Ganesh
collection PubMed
description The activity of tofacitinib for Alopecia areata (AA) has been reported but mainly from the western countries. We report the case of a young female Indian patient with AA unresponsive to therapy. Improvements in terms of hair regrowth were observed within 2 months of treatment with oral tofacitinib 5 mg BID tablets. The effectiveness of tofacitinib in hair regrowth was maintained till 5-month follow-up period. There were no side effects reported and the treatment with tofacitinib was well-tolerated.
format Online
Article
Text
id pubmed-9069910
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-90699102022-05-05 Treatment of Resistant Alopecia areata with Tofacitinib Avhad, Ganesh Int J Trichology Case Report The activity of tofacitinib for Alopecia areata (AA) has been reported but mainly from the western countries. We report the case of a young female Indian patient with AA unresponsive to therapy. Improvements in terms of hair regrowth were observed within 2 months of treatment with oral tofacitinib 5 mg BID tablets. The effectiveness of tofacitinib in hair regrowth was maintained till 5-month follow-up period. There were no side effects reported and the treatment with tofacitinib was well-tolerated. Wolters Kluwer - Medknow 2022 2022-04-04 /pmc/articles/PMC9069910/ /pubmed/35531489 http://dx.doi.org/10.4103/ijt.ijt_128_21 Text en Copyright: © 2022 International Journal of Trichology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Avhad, Ganesh
Treatment of Resistant Alopecia areata with Tofacitinib
title Treatment of Resistant Alopecia areata with Tofacitinib
title_full Treatment of Resistant Alopecia areata with Tofacitinib
title_fullStr Treatment of Resistant Alopecia areata with Tofacitinib
title_full_unstemmed Treatment of Resistant Alopecia areata with Tofacitinib
title_short Treatment of Resistant Alopecia areata with Tofacitinib
title_sort treatment of resistant alopecia areata with tofacitinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069910/
https://www.ncbi.nlm.nih.gov/pubmed/35531489
http://dx.doi.org/10.4103/ijt.ijt_128_21
work_keys_str_mv AT avhadganesh treatmentofresistantalopeciaareatawithtofacitinib

Ejemplares similares